Pulmonary fibrosis is a devastating disease characterized by accumulation of activated fibroblasts and scarring in the lung. While fibroblast activation in physiological wound repair reverses spontaneously, fibroblast activation in fibrosis is aberrantly sustained. Here we identified histone 3 lysine 9 methylation (H3K9me) as a critical epigenetic modification that sustains fibroblast activation by repressing the transcription of genes essential to returning lung fibroblasts to an inactive state. We show that the histone methyltransferase G9a (EHMT2) and chromobox homolog 5 (CBX5, also known as HP1α), which deposit H3K9me marks and assemble an associated repressor complex respectively, are essential to initiation and maintenance of fibroblast activation specifically through epigenetic repression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha gene (PPARGC1A, encoding PGC1α). Both TGFβ and increased matrix stiffness potently inhibit PGC1α expression in lung fibroblasts through engagement of the CBX5/G9a pathway. Inhibition of CBX5/G9a pathway in fibroblasts elevates PGC1α, attenuates TGFβ- and matrix stiffness-promoted H3K9 methylation, and reduces collagen accumulation in the lungs following bleomycin injury. Our results demonstrate that epigenetic silencing mediated by H3K9 methylation is essential for both biochemical and biomechanical fibroblast activation, and that targeting this epigenetic pathway may provide therapeutic benefit by returning lung fibroblasts to quiescence.

Find the latest version:

http://jci.me/127111/pdf
CBX5/G9a/H3K9me-mediated gene repression is essential to fibroblast activation during lung fibrosis.

Authors:
Giovanni Ligresti¹*, Nunzia Caporarello¹, Jeffrey A. Meridew¹, Dakota L. Jones¹, Qi Tan¹, Kyoung M. Choi¹, Andrew J. Haak¹, Aja Aravamudhan¹, Anja C. Roden², YS Prakash¹³, Gwen Lomberk⁴, Raul A. Urrutia⁴, and Daniel J. Tschumperlin¹.

Affiliations:
¹ Department of Physiology & Biomedical Engineering, Mayo Clinic, Rochester, MN
² Laboratory of Medicine & Pathology, Mayo Clinic, Rochester, MN
³ Department of Anesthesiology, Mayo Clinic, Rochester, MN
⁴ Department of Surgery, Division of Research and the Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, WI

Conflict of interest: The authors have declared that no conflict of interest exists.

*Corresponding authors:
Daniel J. Tschumperlin, Ph.D, Mayo Clinic College of Medicine and Science, 200 First Street SW Rochester, MN 55905. E-mail: tschumperlin.daniel@mayo.edu and Giovanni Ligresti, Ph.D., Mayo Clinic College of Medicine and Science, 200 First Street SW Rochester, MN 55905. E-mail: ligresti.giovanni@mayo.edu or ligresti@bu.edu
Abstract

Pulmonary fibrosis is a devastating disease characterized by accumulation of activated fibroblasts and scarring in the lung. While fibroblast activation in physiological wound repair reverses spontaneously, fibroblast activation in fibrosis is aberrantly sustained. Here we identified histone 3 lysine 9 methylation (H3K9me) as a critical epigenetic modification that sustains fibroblast activation by repressing the transcription of genes essential to returning lung fibroblasts to an inactive state. We show that the histone methyltransferase G9a (EHMT2) and chromobox homolog 5 (CBX5, also known as HP1α), which deposit H3K9me marks and assemble an associated repressor complex respectively, are essential to initiation and maintenance of fibroblast activation specifically through epigenetic repression of peroxisome proliferator-activated receptor gamma coactivator 1 alpha gene (PPARGC1A, encoding PGC1α). Both TGFβ and increased matrix stiffness potently inhibit PGC1α expression in lung fibroblasts through engagement of the CBX5/G9a pathway. Inhibition of CBX5/G9a pathway in fibroblasts elevates PGC1α, attenuates TGFβ- and matrix stiffness-promoted H3K9 methylation, and reduces collagen accumulation in the lungs following bleomycin injury. Our results demonstrate that epigenetic silencing mediated by H3K9 methylation is essential for both biochemical and biomechanical fibroblast activation, and that targeting this epigenetic pathway may provide therapeutic benefit by returning lung fibroblasts to quiescence.
Introduction

Pulmonary fibrosis is a devastating condition characterized by progressive accumulation of activated fibroblasts (sometimes referred to as myofibroblasts) and aberrant deposition of extracellular matrix (1-3). Activated fibroblasts arise in normal wound healing responses to promote tissue repair; however, their sustained activation results in pathological scar formation (4, 5). While both biochemical and biomechanical stimuli have been found to drive fibroblast activation and aberrant matrix deposition (6-8), the mechanisms responsible for maintaining persistent and self-sustaining fibrogenesis remain incompletely characterized, posing significant barriers to the development of therapeutic interventions. A growing literature shows that epigenetic mechanisms may be responsible for perpetuating the activated state of fibroblasts by modulating the transcriptional activity of critical pro-fibrotic genes involved in fibrosis progression (9-12). Epigenetic alterations, such as DNA methylation and histone modifications, play important roles in numerous physiological and pathological responses by regulating multiple biological processes including cell differentiation, proliferation and apoptosis (13-15). Altered epigenetic programs in diseased lung fibroblasts are known to contribute to idiopathic pulmonary fibrosis (IPF) (11, 16). While much attention has been given to the epigenetic activation of pro-fibrotic gene expression during lung fibrosis development (11, 17, 18), only recently epigenetic repression of anti-fibrotic genes has become appreciated as a potential mechanism that prevents the return of activated lung fibroblasts to a quiescent state (19-23). Here, we identify the epigenetic repressor CBX5 as a novel regulator of fibroblast activation, acting via its transcriptional inhibitory functions to perpetuate the pathological activated state of diseased lung fibroblasts. CBX5 functions as a gene silencer that binds methylated lysine 9 residue on histone 3 (H3K9me) leading to the assembly of a transcriptional repressor complex (24-26). Our study reveals that CBX5 and the histone methyltransferase G9a, responsible for methylating histone 3 on lysine 9 (27, 28), are important mediators of lung fibroblast activation in
response to both biochemical and mechanical stimuli in vitro, and in vivo we show that their functions within lung fibroblasts are essential to lung fibrogenesis.

Mechanistically, we find that CBX5 and G9a directly alter chromatin landscape and repress transcription of the gene encoding PPARγ coactivator 1 alpha (PGC1α), a master regulator of fatty acid oxidation and mitochondrial metabolism (29, 30). PGC1α de-repression is essential to the anti-fibrotic effects of CBX5/G9a inhibition, identifying PGC1α as a novel and potent regulator of fibroblast fate. Previous reports have shown that inhibition of PGC1α in skeletal muscle leads to alterations in mitochondrial metabolism, including reduced oxidative phosphorylation (30). Interestingly, mitochondrial dysfunction has been shown to play a role in the development of IPF (31), suggesting that loss of mitochondrial gene expression due to epigenetic alterations may be important to the dysfunctional metabolism observed in this disease. Hence, our data shed new light on G9a/CBX5/H3K9me as critical regulators of fibroblast activation, and identify epigenetic repression of PGC1α as a key mechanism promoting diseased lung fibroblast activation in support of lung fibrosis. Targeted inhibition of this epigenetic repression program may represent an important therapeutic strategy to reverse fibroblast activation and halt progressive lung fibrogenesis.
Results

Identification of CBX5 as a novel epigenetic regulator of fibroblast activation

To identify novel regulators of lung fibroblast activation during lung fibrosis progression, we recently completed a high-content siRNA screen of gene regulators of αSMA+ stress fibers in human lung fibroblasts (32). Through this screen we identified the epigenetic regulators BRD4, which has already been linked to fibroblast activation and lung fibrosis (17, 18, 33), as well as CBX5, which has not previously been linked to fibroblast activation. Both of these epigenetic regulators are known for their interaction with histone 3 (H3) and for their role as global regulators of gene transcription (34, 35). BRD4 binds acetylated lysine 4 on histone 3 (H3) facilitating gene transcription, whereas CBX5 has high affinity for methylated lysine 9 (di-tri-methylated) on H3 and supports transcriptional repression. These findings suggest that contrasting positive and negative epigenetic control mechanisms may be critical for orchestrating fibroblast activation. While important roles for BRD4 and H3K4 acetylation-mediated gene activation are well established during fibrogenesis (36), the function of the epigenetic repressor CBX5 and H3K9 methylation-mediated gene repression during lung fibrosis is not fully elucidated. To further investigate the role of CBX5 in fibroblast activation, we performed siRNA knockdown of CBX5 in IMR90 fibroblasts and evaluated the effect on TGFβ-induced pro-fibrotic gene expression. CBX5 silencing significantly attenuated the expression of ACTA2, COL1A1 and FN1 (Figure1A), hallmarks of fibroblast activation and ECM production. Similarly, Western blotting analysis demonstrated that CBX5 knockdown in TGFβ-treated lung fibroblasts blocked αSMA expression (Figure1B). To relate pro-fibrotic gene expression to de novo matrix synthesis and deposition, we adapted an antibody-based detection method to quantify fibroblast-deposited fibronectin and collagen I (37). We observed that CBX5 knockdown in lung fibroblasts strongly inhibited TGFβ-induced ECM protein deposition (Figure1C). In order to evaluate whether CBX5 contributes to migratory responses we performed a wound healing
assay and found that cell migration in the presence of TGFβ was significantly impaired in CBX5-silenced fibroblast compared to control cells (Figure 1D).

Prior work has demonstrated stable phenotypic alterations in fibroblasts isolated from patients with IPF suggesting an epigenetic control of fibroblast activation (38-40). Therefore, we also performed siRNA mediated knockdown of CBX5 in IPF-derived fibroblasts. Similar to our observation in TGFβ-stimulated normal fibroblasts, CBX5 knockdown significantly attenuated TGFβ pro-fibrotic functions in these diseased fibroblasts (Figure 1E). Interestingly, CBX5 knockdown significantly reduced pro-fibrotic gene expression even in absence of exogenous TGFβ (Figure 1F) supporting a role for CBX5 in sustaining IPF-derived fibroblast activation during serial passage in vitro. Together these findings indicate a broad relevance of CBX5 to ECM gene expression, matrix production and cell migration in both TGFβ-stimulated and IPF-derived fibroblasts consistent with an important role for this epigenetic repressor in initiating and sustaining fibroblast activation. Given that CBX5 behaves as transcriptional repressor and its inhibition blocks fibroblast activation, we hypothesized that CBX5 may directly contribute to the repression of genes whose function is critical to maintain or return fibroblasts to an inactive state (Figure 1G).

**Inhibition of the histone methyltransferase G9a blocks biochemical and biomechanical fibroblast activation.**

CBX5 binds methylated lysine 9 on histone 3 (H3K9me) leading to the assembly of a transcriptional repressor complex that potently inhibits gene transcription (26). In addition to biochemical stimulation via TGFβ leading to fibroblast activation, previous work has demonstrated that the pathological stiff environment present in fibrotic lungs also directly influences fibroblast activation (6, 7, 41). Although the role of matrix stiffness in influencing the transcriptional machinery of lung fibroblasts to promote their activation is well established (42-
the contribution of epigenetic remodeling and, more specifically, H3K9 methylation-mediated gene repression in regulating pathological mechanoresponses remain unexplored.

To evaluate whether matrix stiffness and TGFβ directly influence global H3K9 methylation, we isolated primary mouse lung fibroblasts by FACS sorting and cultured them for 72 hours on soft or stiff substrates followed by immunofluorescence analyses using an antibody against H3K9me2/3 marks as well as an antibody against αSMA to monitor cell activation. We found that lung fibroblasts cultured on stiff matrices displayed higher αSMA expression and elevated global H3K9 methylation compared to fibroblasts cultured on physiologically soft substrates (Figure 2A). To build on these observations, we compared the levels of global H3K9 methylation in normal human lung fibroblasts that have been cultured for 24 hours on soft (0.2kPa) or stiff (64kPa and Plastic) substrates in presence of absence of TGFβ. Western blotting analysis showed that the increased αSMA expression in fibroblasts cultured on stiff substrates was accompanied by strong H3K9 methylation and this effect was further amplified by the presence of TGFβ in the culture media (Figure 2B).

H3K9 methylation (di- and tri-methylation) is a mark of heterochromatin, a transcriptionally inactive state of chromatin (25, 27, 45). Beside binding both di- and tri-methylated lysine 9 on histone 3, CBX5 forms complexes with several others non-histone proteins, including DNA methyltransferases (46, 47), histone methyltransferases (48), and histone deacetylases (49) which together with CBX5, participate in the repression of gene transcription. As we determined that both matrix stiffness and TGFβ are important drivers of H3K9 methylation in lung fibroblasts, we reasoned that H3K9me mark deposition by a histone methyltransferase (HMT) may be critical to promote fibroblast activation in response to biomechanical or biochemical stimuli. We therefore cultured normal human lung fibroblasts on soft or stiff substrates for 24
hours in presence or absence of a small molecule inhibitor (BIX01294) that specifically blocks the enzymatic activity the G9a histone methyltransferase (50) which is known to both bind CBX5 (48) and promote H3K9 methylation (28), and has recently been implicated in IPF fibroblast genetic repression (22, 51). BIX01294 treatment prevented matrix stiffness-induced αSMA upregulation and reduced the levels of H3K9 methylation in lung fibroblasts (Figure2C), suggesting that G9a-induced H3K9 methylation is required to promote fibroblast activation in response to biomechanical stimuli. While matrix stiffness stimulates both H3K9me2 and H3K9me3 mark deposition in lung fibroblasts, inhibition of G9a in these cells by BIX01294 reduced H3K9me2 but had no effect on H3K9me3 mark deposition, indicating that H3K9 di-methylation is directly implicated in mediating fibroblast mechanoresponses. Additionally, BIX01294 dose-dependently blocked αSMA expression following TGFβ stimulation in normal lung fibroblasts plated on stiff plastic substrates (Figure2D). Time-course experiments further confirmed the capacity of BIX01294 to block H3K9 di-methylation as early as 2 hours in lung fibroblasts cultured on stiff plastic substrates (Figure2E).

Contractile force generation is an important function of activated fibroblasts (52, 53). We found that inhibition of G9a using siRNA significantly reduced cellular contractility as demonstrated by traction force microscopy (TFM) (Figure2F), and by the collagen gel contraction assay (Figure2G), matching the effect of CBX5 siRNA. To extend our observations and evaluate the effect of inhibiting G9a in diseased fibroblasts, we treated IPF-derived fibroblasts with TGFβ for 24 hours in presence or absence of BIX01294 or G9a siRNA. Both BIX01294 and G9a siRNA significantly reduced pro-fibrotic gene expression, consistent with a critical role for G9a in maintaining the activated state of disease-derived cells (Figure2H,I). Taken together these findings demonstrate that lung fibroblast H3K9 methylation is responsive to disease-relevant biochemical and biomechanical stimuli, and that the histone methyltransferase G9a is essential
to both responses. Moreover, inhibition of G9a in IPF-derived fibroblasts blunted their activation in the presence or absence of TGFβ, indicating that diseased fibroblasts remain responsive to pharmacologic targeting of G9a.

To investigate the direct disease relevance of these findings, we next probed G9a expression/localization in lung fibroblasts during experimental lung fibrogenesis in mice expressing Col1α1-GFP. Histological examination of the lungs from bleomycin-treated mice showed robust expansion of GFP-labeled cells compared to those from sham animals (Figure 3A). Additionally, a close examination of the lung tissue revealed increased expression of G9a in lung fibroblasts from bleomycin-treated lungs compared to lungs from sham animals (Figure 3B), suggesting that G9a may be involved in fibroblast activation during lung fibrogenesis. To extend these observations to H3K9 modifications, we stained both diseased mouse and human lung tissues with an antibody against H3K9 di-methylation and found strong immunostaining in GFP-labeled cells following bleomycin challenge compared to sham mice (Figure 3C). Similarly, we observed strong co-localization of fibronectin and H3K9 di-methylation in fibrotic regions of IPF lungs (Figure 3D) supporting potential relevance of G9a in the development and progression of IPF. Next, we evaluated G9a and CBX5 expression by Western blotting in IPF-derived fibroblasts relative to healthy fibroblasts and found that while there was no statistical difference in G9a, CBX5 expression was significantly elevated in IPF fibroblasts compared to normal ones, suggesting a role for CBX5 in sustaining fibroblasts activation ex vivo (Figure 3E).
*In vivo* activated lung fibroblasts are characterized by enhanced ECM deposition and stable repression of peroxisomal genes.

Given that the CBX5/G9a pathway plays a role in epigenetically repressing gene transcription (48), we hypothesized that this epigenetic complex must repress expression of genes that actively maintain or restore the quiescent state of lung fibroblasts. Rather than relying solely on in vitro activation studies to identify disease relevant fibrosis suppressor genes, we employed the bleomycin model to generate fibrosis in mice to study the activated state of freshly isolated lung fibroblasts. To identify the fibroblast population of the mouse lungs, we again used the *Col1α1*-GFP transgenic mouse, in which cells with a transcriptionally active *Col1α1* promoter are GFP labeled. In addition, antibodies against known markers for leukocytes (CD45), endothelial (CD31) and epithelial cells (CD326) were also included in the FACS sorting to further ensure an optimal separation of the fibroblast from other cell populations of the lung (Figure 4A). Two weeks following bleomycin administration diseased and normal lungs were harvested, minced to generate a single cell suspension, and subjected to FACS. To identify genes whose expression is reduced during fibroblast activation, we evaluated the expression of genes in FACS-isolated lung fibroblasts from sham and bleomycin treated animals. Based on an extensive literature linking peroxisomal genes to inhibition of fibroblast activation (54-57), we focused on family members PPARα, PPARγ, and their co-regulator PGC1α. In freshly isolated lung fibroblasts from bleomycin-treated mice we observed significant upregulation of *Fn1* gene expression and strong repression of *Ppara* and *Ppargc1a* genes compared to lung fibroblasts from sham animals. Surprisingly, despite the established role of PPARγ in fibrosis (57), we did not observe a significant difference in the expression of this gene between bleomycin-treated and normal lung fibroblasts (Figure 4B). To assess whether the disease activated state is maintained in vitro, freshly isolated GFP+ lung fibroblasts from sham and bleomycin-treated mice were cultured for one week followed by Western Blotting analysis to evaluate pro-and anti-
fibrotic gene expression. As shown in Figure 4C, lung fibroblasts isolated from bleomycin-treated mice displayed strong αSMA expression and sustained differences in PPARα and PGC1α protein levels relative to fibroblasts from sham treated mice. In addition, in situ ECM deposition measurements revealed that in vivo activated fibroblasts generate significantly more collagen than those isolated from healthy lungs after 1 week in culture. Inhibition of G9a by BIX01294 reduced collagen deposition in these cells to a level that was comparable to control healthy fibroblasts (Figure 4D), demonstrating their responsiveness to G9a inhibition. To assess whether inhibition of G9a in vivo using BIX01294 restored/elevated peroxisomal gene expression in lung fibroblasts following lung injury, we treated mice with bleomycin and ten days following instillation we i.p. injected them with a single dose of BIX01294 (5mg/kg) followed by lung fibroblast isolation by FACS sorting (Figure 4E). In order to evaluate the efficacy of BIX01294 in blocking H3K9 methylation in vivo we set up a parallel experiment in which global H3K9 methylation was evaluated in whole lung by Western blotting at 6, 24 and 48 hours following the delivery of a single dose of BIX01294. As shown in Figure 4F, BIX01294 treatment reduced global H3K9 methylation in whole lung compared to vehicle and this effect was detectable at 24 hours and 48 hours following BIX01294 injection. Additionally, qPCR analysis showed elevated Ppargc1a and Ppara gene expression in fibroblasts isolated from the lungs of BIX01294-treated animals compared to DMSO-treated control lungs (Figure 4G), demonstrating that pharmacological manipulation of epigenetic mechanisms restored peroxisomal gene expression in diseased lung fibroblasts, potentially altering their fibrogenic behavior.

**Inhibition of CBX5 in activated lung fibroblasts restores peroxisomal gene expression.**

To test whether peroxisomal proteins are acutely regulated by TGFβ, we measured each by Western blotting and confirmed TGFβ-mediated reductions in expression in both normal and IPF-derived fibroblasts (Figure 5A,C). To test the role for CBX5 in TGFβ-mediated peroxisomal
gene repression, we compared cells treated with CBX5 siRNA (48 hours) followed by TGFβ treatment for 24 hours. Transcripts for all three peroxisomal genes were potently repressed by TGFβ and this repression was prevented by CBX5 siRNA (Figure5B,D). To extend these observations to matrix stiffness-mediated fibroblast activation, we cultured normal lung fibroblasts on soft/stiff substrates for 24 hours and evaluated peroxisomal gene expression by qPCR. Interestingly, fibroblasts cultured on pathologically stiff substrates showed strong inhibition of both PPARC1A and PPARA gene expression but not PPAR compared to those cultured on substrates of normal compliance (Figure5E). Inhibition of CBX5 by siRNA in fibroblasts cultured on stiff substrates fully restored PGC1α and PPARα expression (Figure5F), demonstrating that this epigenetic reader is essential to matrix stiffness-mediated peroxisomal gene repression. Together our results demonstrate that CBX5 mediates repression of putative fibrosis-suppressor peroxisomal genes in response to TGFβ and matrix stiffness, and the same genes are repressed in vivo in fibroblasts during experimental lung fibrosis (Figure4B).

Interestingly, inhibition of the other epigenetic regulator identified in our prior screen, BRD4, was similarly effective in reducing pro-fibrotic gene expression, but had the opposite effect on PPARC1A relative to G9a inhibition (FigureS1). This result confirms the overall important roles of epigenetic regulators in fibroblast activation, but also emphasizes the likelihood that their specific effects on fibroblast fate beyond reducing canonical activation genes may be distinct and important.

PGC1α plays a leading role as a fibrosis-suppressor gene in lung fibroblasts.

To determine whether inhibition of G9a-induced H3K9 methylation by BIX01294 replicated the results obtained with CBX5 silencing in lung fibroblasts, we first cultured IPF-derived fibroblasts in presence or absence of BIX01294 for 2, 4 and 6 hours followed by Western blotting analysis to evaluate global H3K9 methylation. As shown in Figure6A, BIX01294 reduced H3K9
methylation starting at 2-4 hours after exposure. This rapid kinetic profile prompted us to evaluate the effects of BIX01294 on TGFβ-stimulated pro-fibrotic gene expression during the first 12 hours following TGFβ treatment. BIX01294 inhibited TGFβ-induced ACTA2 and COL1A1 gene expression at 12 hours (Figure6B) and blocked TGFβ-mediated PPARGC1A gene repression starting at 4 hours (Figure6C), demonstrating that BIX01294-mediated PPARGC1A elevation preceded the reduction of pro-fibrotic genes. Intriguingly, BIX01294 failed to restore PPARα and PPARγ gene expression at these time points, suggesting that these peroxisomal genes might not directly contribute to the anti-fibrotic effects of BIX01294 (Figure6C).

Furthermore, BIX01294 significantly elevated PPARGC1A gene expression at 8 hours and blocked ACTA2 gene expression at 12 hours in IPF fibroblasts that have not been treated with TGFβ (Figure6D), confirming similar kinetics and therapeutic sensitivity in disease-derived fibroblasts. Taken together, these observations suggest a potential leading role for PPARGC1A gene activation in attenuating fibroblast activation downstream of G9a inhibition.

To rule out the involvement of PPARγ and PPARα in mediating the anti-fibrotic effects of inhibiting G9a or CBX5 in lung fibroblasts, we individually blocked their activity using either small molecule antagonists or siRNAs in presence of absence of BIX01294 or CBX5 siRNA. Neither an antagonist of PPARγ nor PPARγ siRNA prevented the BIX01294- or CBX5 siRNA-mediated inhibition of ACTA2 gene expression in these cells, demonstrating that the beneficial effects of inhibiting CBX5/G9a are PPARγ independent (Figure6E). Moreover, while PPARα siRNA was partially effective (Figure6F), PGC1α siRNA fully reversed the CBX5 siRNA- and BIX01294-mediated inhibition of ACTA2 gene expression (Figure6G) and reversed the CBX5 siRNA-mediated inhibition of COL1A1 gene expression in responses to TGFβ (Figure6H).

These results confirm that repression of PGC1α, in a CBX5/G9a-dependent fashion, is an early and essential event in TGFβ-induced lung fibroblast activation.
CBX5 directly interacts with PPARGC1A gene promoter.

Having demonstrated the key role of CBX5 and H3K9 methylation in promoting PPARGC1A gene repression, we sought to establish their direct interactions with the PPARGC1A gene promoter. To first evaluate whether CBX5 binds PPARGC1A gene proximal promoter we carried out a chromatin immunoprecipitation analysis (ChIP) and assayed CBX5 binding at three different regions of PPARGC1A gene promoter that were previously shown to contain consensus sequences for numerous transcription factors (29). ChIP analysis demonstrated binding of CBX5 to all three regions and also revealed that this interaction was further increased by TGFβ (Figure 7A), and reduced by CBX5 siRNA (Figure S2). Similarly, H3K9me2 mark enrichment was also increased at the same genomic locations as a result of TGFβ stimulation and this enrichment was attenuated in all three locations by BIX01294, thereby confirming that TGFβ-mediated H3K9 methylation at PPARGC1A gene promoter is dependent on G9a activity (Figure 7B). These findings delineate a novel mechanism by which TGFβ induces epigenetic remodeling of PPARGC1A gene promoter to facilitate its repression and promote fibroblast activation.

Two of the CBX5 binding sites (-159 +85 and -377 -282) on the PPARGC1A gene promoter are positioned in close proximity to the transcription starting site (TSS) and contain known consensus binding sites for the cAMP response element-binding transcription factor CREB (29). CREB is well known to be activated by the cAMP/PKA signaling pathway to promote the transcription of numerous genes (58). Interestingly, previous publications reported deficient activation of cAMP/PKA/CREB signaling pathway in fibroblasts isolated from fibrotic lungs (59). To explore the relevance of CREB in the repression of PGC1α by TGFβ, and link H3K9 methylation to cAMP/PKA signaling pathway, we inhibited both CBX5 and CREB in TGFβ-stimulated lung fibroblasts. Inhibition of CBX5 alone promoted PPARGC1A gene expression in TGFβ-treated fibroblasts, while knockdown of CREB in these cells blocked this transcriptional
elevation (Figure 7C). In addition, similarly to what we observed in PGC1α-silenced lung fibroblasts, CREB knockdown elevated ACTA2 gene expression and partially blocked the anti-fibrotic effects of inhibiting CBX5 in these activated cells (Figure 7D). These findings identify CREB as an important transcription factor upstream of PGC1α and reveal that inhibition of CBX5/G9a pathway in activated lung fibroblasts facilitates CREB-mediated PPARGC1A transcription to attenuate fibrogenic cell activation. Based on the altered H3K9 methylation observed in fibrotic lung tissues, we expect that CBX5 genomic residence during lung fibrosis development may inhibit the interaction of CREB with PPARGC1A gene promoter resulting in reduced gene transcription, thereby supporting ongoing fibroblast activation in vivo (Figure 7E).

Inhibition of G9a restores Ppargc1a gene expression in vivo and attenuates fibrosis progression.

We previously showed that G9a inhibitor BIX01294 acutely elevates fibroblast Ppargc1a expression in vivo (Figure 4G). To test whether inhibition of G9a by BIX01294 is capable of stably elevating Ppargc1a gene expression in the lung and altering the trajectory of experimental fibrosis, we treated mice with bleomycin followed by intraperitoneal administration of a single dose of BIX01294 (5mg/kg) or vehicle, delivered at day 10 (Figure 8A). Ten days following BIX01294 treatment lungs were harvested and qPCR was performed to assess Ppargc1a gene expression. As shown in Figure 8B, Ppargc1a gene was strongly repressed at day 10 following bleomycin and its expression partially spontaneously recovered by day 20 post-bleomycin. Interestingly, BIX01294 treatment at day 10 significantly elevated Ppargc1a gene expression in whole lung at day 20 compared to vehicle control, thereby providing an important tool to manipulate Ppargc1a gene expression during the progression of lung fibrosis. Gene expression analysis of disease-relevant genes also showed that both Fn1 and Ctgf gene expression were significantly elevated in bleomycin-treated lungs compared to sham, and
BIX01294 treatment significantly attenuated their expression compared to vehicle (Figure8C,D). Histological examination revealed profound fibrotic remodeling in bleomycin-treated mice, and a trend toward improved tissue architecture in animals that received a single dose of BIX01294 (Figure8E,F), though this effect did not reach statistical significance. Consistent with these observations, bleomycin-treated lungs showed a significant increase in hydroxyproline content which was partially, but not significantly reduced in the lungs of BIX01294-treated mice (Figure8G). These latest observations, while failing to reach statistical significance, are supported by recent papers reporting the beneficial effects of BIX01294 in mouse models of kidney and peritoneal fibrosis (60, 61).

To directly investigate the contribution of G9a deletion in fibroblast activation during lung fibrosis, we used a conditional strategy to target G9a specifically in fibroblasts by generating mice with tamoxifen-inducible deletion in COL1α2-expressing cells. To do this we crossed g9a floxed mice (g9afl/fl) with transgenic mice expressing a tamoxifen-dependent Cre-ER(T) fusion protein under the control of the promoter for procollagen1α2 gene (Col1a2-CreER(T)). To evaluate the fibrogenic response of the lungs, five doses of tamoxifen (once daily) were administered in these transgenic animals starting at day 3 following bleomycin administration (Figure8H). Immunofluorescence analysis of bleomycin-treated lungs harvested at day 21 showed absence of nuclear G9a and reduced H3K9me2 in PDGFRα-expressing cells demonstrating successful deletion of g9a gene in lung fibroblasts (Figure8I,K). Histological examination revealed significant fibrosis in bleomycin-treated Col1a2-CreER(T):g9afl/fl that did not receive tamoxifen and in bleomycin-treated controls (g9afl/fl and Col1a2-CreER(T)) that received tamoxifen compared to sham animals. No significant changes, however, were observed in the lung architecture of bleomycin-treated Col1a2-CreER(T):g9afl/fl mice treated with tamoxifen compared to sham animals (Figure8J,L). Additionally, hydroxyproline content was
significantly elevated in the lungs of control mice (bleomycin-treated \textit{Col1a2-CreER(T):g9a}^{\text{fl/fl}} mice that did not receive tamoxifen as well as tamoxifen treated \textit{Col1a2-CreER(T)} and \textit{g9a}^{\text{fl/fl}} controls), but not in those with fibroblast-specific conditional deletion of \textit{g9a} (\textit{Col1a2-CreER(T):g9a}^{\text{fl/fl}} mice treated with tamoxifen) (Figure 8M). These observations demonstrate that G9a plays direct roles in lung fibroblast activation in vivo and are essential to pathological collagen deposition.

An important comparison here is between the efficacy of the global G9a inhibitor treatment and the statistically superior fibroblast-targeted deletion of G9a. While these experiments differ in the approach (pharmacologic and genetic) and time course, they suggest that non-fibroblast effects of G9a inhibition may complicate its net in vivo efficacy. Taken together our findings thus demonstrate an important role for G9a inhibition in restoring \textit{Ppargc1a} gene expression in fibrotic lungs and in attenuating the activated fibroblast phenotype. Moreover, these results shed light on the novel concept that promoting gene transcription through targeted epigenetic intervention may represent an appealing strategy aimed at restoring the altered transcriptional imbalance that promotes lung fibrosis progression.
Discussion

In this work we demonstrate that CBX5/G9a/H3K9me-mediated gene repression is critical to initiate and perpetuate lung fibroblast activation in response to both biochemical and biomechanical stimuli. Mechanistically, we show that this pathway epigenetically represses PPARGC1A gene and PGC1α protein expression and this repression is required for sustained fibrogenic activation. Gene expression analysis of FACS-sorted mouse fibroblasts isolated from the lungs of bleomycin-treated animals showed that Ppargc1a gene expression is markedly decreased in vivo during fibrosis, while immunofluorescence imaging from both diseased mouse and human IPF lungs confirmed strong H3K9me in areas of active fibrogenesis. Diseased lung fibroblasts isolated from bleomycin-treated mice displayed stably reduced PGC1α expression and elevated ECM protein deposition even when cultured in vitro, demonstrating a “fibrogenic memory” in vitro that appears dependent on epigenetic gene repression to sustain their activated state. Interestingly, we demonstrated elevation of CBX5 expression in IPF-derived compared to normal fibroblasts, suggesting a potential role for CBX5 in perpetuating fibroblast activation ex vivo. Most importantly, inhibition of the G9a/CBX5 pathway in diseased mouse or human lung fibroblasts restored PGC1α expression and strongly attenuated their fibrogenic activation. Additionally, global inhibition of G9a in vivo by BIX01294 elevated Ppargc1a gene expression and partially attenuated lung fibrosis in mice challenged with bleomycin compared to control animals, suggesting that targeting this epigenetic repressive mechanism may have therapeutic benefits.

PGC1α is the co-activator of the peroxisomal family member PPARγ, and is well known for its critical role during mitochondria biogenesis and fatty acid metabolism (29, 30). Interestingly, both mitochondrial dysfunction and deficient fatty acid metabolism have been shown to contribute to the development of fibrosis in multiple organs (31, 62, 63). In this regard, it has recently been shown that loss of PGC1α in lung alveolar epithelial cells leads to multiple
mitochondrial perturbations, including deficient oxidative respiration and misregulated apoptosis which directly contributes to the development of interstitial fibrogenesis (64). Additionally, a recent paper revealed that renal tubular epithelial cells critically depend on fatty acid oxidation as their energy source, and reduced PGC1α expression has been observed in epithelial cells of the kidneys of patients with chronic kidney disease, supporting a protective role for PGC1α in the setting of chronic diseases (62). Although these recent publications demonstrate that the loss of PGC1α in epithelial cells contributes to the development of kidney and lung fibrosis, the role of PGC1α in fibroblast activation, its loss in disease settings, and the mechanisms responsible for its gene repression have not been previously studied. Our work identifies an inhibitory epigenetic mechanism responsible for the transcriptional repression of PGC1α in diseased lung fibroblasts and reveals, for the first time, that PGC1α is essential to restrain fibroblast activation, thereby identifying a novel epigenetic foundation that underpins the switch between lung fibroblast quiescence and activation through repression of a fibrosis suppressor gene.

In the context of TGFβ signaling, our findings demonstrate that PGC1α is a direct target of a repressive program initiated through the engagement of the G9a/CBX5 epigenetic pathway, and that the repression of PGC1α is essential to fibroblast activation by TGFβ. Interestingly, even in the absence of TGFβ, BIX01294 elevated PPARGC1A gene expression in IPF-derived fibroblasts and this elevation preceded the attenuation of ACTA2 gene expression, further suggesting that G9a-mediated PPARGC1A gene repression is essential to the persistent fibrogenic activation of these cells. Other epigenetic transcriptional repressors, such as histone deacetylases (HDACs) and DNA methyltransferases (DNMT1) have been shown to play a role in TGFβ signaling and contribute to sustained fibrogenesis (11, 21, 65, 66). Intriguingly, multiple HDACs including HDAC5 and HDAC9, as well as DNMT1, have been shown to directly interact
with CBX5 to maximize their repressive functions (35, 49), suggesting that CBX5 might orchestrate a platform of multiple epigenetic repressors to ensure stable silencing of fibrosis suppressor genes.

In addition to exerting its repressive function on \textit{PPARGC1A} gene, we found that TGF\(\beta\) potently repressed \textit{PPARA} and \textit{PPARG} two genes that are closely related to, and transcriptionally regulate, \textit{PPARGC1A} (67), suggesting that repression of these genes by TGF\(\beta\) may diminish \textit{PPARGC1A} gene transcription. Numerous studies have identified important roles of PPAR\(\alpha\) and PPAR\(\gamma\) in regulating processes related to fibrogenesis, including cellular differentiation, inflammation, and wound healing (54, 56). PPAR\(\alpha\) agonists inhibit the production of collagen by hepatic stellate cells and inhibit liver, kidney, and cardiac fibrosis in animal models (68-70). In the bleomycin model of lung fibrosis PPAR\(\alpha\) agonists significantly inhibit the fibrotic response, while PPAR\(\alpha\) deficient mice developed more serious fibrosis (71). Interestingly, while we confirmed that inhibition of G9a by BIX01294 blocked TGF\(\beta\)-induced \textit{PPARGC1A} gene repression at 4 hours, and significantly blocked TGF\(\beta\) pro-fibrotic responses within 12 hours, we did not observed \textit{PPARA} or \textit{PPARG} restoration by BIX01294, demonstrating that these genes are not directly responsible for the anti-fibrotic effect of BIX01294. Similarly to what we found using the G9a inhibitor BIX01294, only inhibition of PGC1\(\alpha\) fully reversed the CBX5 siRNA-mediated inhibition of \textit{ACTA2} gene expression, confirming the leading role of PGC1\(\alpha\) as a fibrosis suppressor in our studies. Intriguingly, previous studies on liver fibrosis have demonstrated a direct contribution for MeCP2 and EZH2, two epigenetic repressors involved in H3K9 and H3K27 methylation respectively and CBX5 binding (25, 35), in TGF\(\beta\)-mediated PPAR\(\gamma\) repression and hepatic stellate cell activation (72). Similarly, while our finding support a direct role for CBX5 in promoting TGF\(\beta\)-induced \textit{PPARG} gene repression in lung fibroblasts, only CBX5 but not G9a inhibition in these cells rescued \textit{PPARG} gene expression, suggesting
that different epigenetic dynamics may control peroxisomal gene repression in lung and liver mesenchymal cells to promote their activation.

In addition to their responsiveness to TGFβ, lung fibroblasts are exquisitely sensitive to the mechanical milieu of the lung (42). In fibrotic scar tissue, the mechanical environment is profoundly altered and increases in the tissue stiffness directly contribute to fibroblast activation (73). Although previous studies have shown that mechanical cues and matrix stiffness can alter nuclear functions including chromatin organization (73), no prior studies have addressed the role of histone modification, especially H3K9 methylation, during fibroblast activation as a result of the altered lung mechanical microenvironment. Our work demonstrates that lung fibroblasts cultured on pathologically stiff substrates are characterized by elevated global H3K9 methylation compared to those cultured on physiologically compliant substrates. Inhibition of G9a or CBX5 strongly inhibited matrix stiffness-induced global H3K9 methylation and reduced αSMA expression and traction forces, thereby confirming the relevance of H3K9 methylation during fibroblast mechanoactivation. Interestingly, our findings are in line with a recent paper showing that in cancer cells mechanical signals generated from rigid substrates promote epigenetic remodeling through H3K9 methylation-mediated gene repression (74). Intriguingly, inhibition of Cdc42, a critical regulator of cytoskeletal assembly, reduced H3K9 methylation in cancer cells that were in contact with stiff substrates. These observations, together with our data, suggest that tension-dependent cytoskeletal mechanotransduction may alter chromatin organization to promote repressive mark deposition in genomic regions containing tumor- or fibrosis-suppressor genes. In line with these observations, immunostaining of histological sections of bleomycin-treated lungs as well as lung tissue from IPF patients, revealed elevated global H3K9 methylation in fibrotic region of the lung that displayed abundant ECM deposition suggesting that the in vivo environment of the lung may directly influence chromatin state. While earlier studies have shown that nucleus-cytoskeleton interconnectivity regulates genome-wide
transcriptional responses to substrate rigidity (73), the epigenetic mechanisms underlying these responses have not been fully investigated. Our work partially fills this gap and demonstrates that the G9a/CBX5 epigenetic pathway plays a critical role in the mechanoresponses of lung fibroblasts by translating mechanical signals into chromatin alterations that promote gene repression in support of fibroblast activation. Although in this paper we did not directly investigate the mechanosignaling pathway leading to the increased H3K9 methylation, we speculate that the profound cytoskeleton alterations that take place in fibroblasts interacting with a pathological stiff environment may directly influence nuclear dynamics and chromatin organization, as supported by recent studies reporting G9a and CBX5 interactions with the nuclear envelope (75, 76). Together our observations shed new light on the role of G9a/CBX5/H3K9me epigenetic pathway during fibroblast activation in response to mechanical and biochemical cues and set the stage for future investigations aimed at understanding how these signals alter nuclear and chromatin dynamics to orchestrate gene repression and promote fibroblast activation.

Finally, given that epigenetic alterations are transmissible and can perpetuate the altered state of the cell through cell division, our findings provide a strong rationale for targeting epigenetically repressed genes such as PPARGC1A in diseased lung fibroblast to reestablish their quiescence and halt progressive lung fibrogenesis. In this regard, G9a inhibition by BIX01294 in mice that have been challenged with bleomycin strongly reduced global H3K9 methylation in whole lung, elevated PPARGC1A gene expression and showed a trend toward beneficial effect in limiting fibrosis progression. Cell specific genetic targeting of G9a in fibroblasts was even more effective in reducing experimental fibrosis. Although drugs that target epigenetic regulators have been approved for the treatment of cancer, this type of therapeutic intervention has not been advanced to treat fibrogenic disorders. Our data underlines the importance of exploring epigenetic gene repression as a potentially targetable mechanism to
reverse the pathological activated state of lung fibroblasts and more broadly halt lung fibrosis progression.
Methods

Cell culture
Cells were maintained in EMEM (ATCC) containing 10% FBS, 1% Antibiotics. IMR-90 embryonic lung fibroblasts were purchased from ATCC. Primary human lung fibroblasts isolated by explant culture from the lungs of subjects diagnosed with IPF who underwent lung transplantation, or donors (HLF) whose organs were rejected for transplantation (non-IPF) were kindly provided by Peter Bitterman and Craig Henke at the University of Minnesota under a protocol approved by the University of Minnesota Institutional Review Board. All primary cell culture experiments were performed with cells at passage six or less.

Reagents
BIX01294 (Cat# B9311) and (+)-JQ1 (Cat# SML1524) were from Sigma-Aldrich.

Human Samples
Healthy lung samples were from surgical resections of patients undergoing thoracic surgery at St. Mary’s Hospital, Mayo Clinic Rochester for focal pathologies (e.g. primary lung cancers without metastases; bronchoalveolar carcinoma and infectious pathologies excluded) and IPF lung samples were obtained from patients who underwent lung transplantation. Both healthy and IPF lung were collected under a protocol approved by the Mayo Clinic Institutional Review Board. Informed consent was obtained from subjects or their legal guardians during initial medical workup.

Mice
Col1α1-GFP transgenic mice were generated as previously described (UC San Diego, La Jolla, CA) (77) and kindly provided by Dr. Derek Radisky. Conditional COL1α2 cell-specific g9a
(Col1a2-CreER(T)-g9a<sup>fl/fl</sup>) were generated by breeding of Col1a2-CreER(T) mice (Jackson Laboratory) with g9a<sup>fl/fl</sup> mice. Eight weeks old female and male C57/BL6 mice were purchased from Jackson Laboratories.

**RNA interference**

RNA interference was performed using Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific, Waltham, MA, USA) as described in the online supplement.

**Immunofluorescence staining**

Mouse and human tissues were immunostained by using Fibronectin I (Santa Cruz, sc-9068), H3K9me2 (Cell signaling, 4658S), αSMA (Sigma-Aldrich, F3777), and G9a (Abcam, ab40542) primary antibodies, as described in the online supplement.

**Fibrosis evaluation**

Seven µm thick sections were cut from Paraffin embedded lung tissues, and the sections were stained either with hematoxylin and eosin (H&E) or with Masson’s Trichrome stain kit (Abcam). All H&E-stained slides and trichrome-stained slides were reviewed in a blinded fashion by a thoracic pathologist. The severity of the fibrosis was evaluated using Ashcroft score: 0 (no fibrosis), 1 (minimal interstitial and/or peribronchiolar thickening due to fibrosis), 3 (moderate thickening without obvious architectural distortion), 5 (increased fibrosis with formation of fibrous bands and/or small masses), 7 (severe architectural distortion with large areas of fibrosis and areas of honeycomb changes), and 8 (total fibrous obliteration of the field) (78). The mean of all scores was calculated for each mouse. Hydroxyproline content was measured using a hydroxyproline assay kit (Biovision), as described in the online supplement.
Traction force microscopy (TFM).

Traction analysis was performed as previously described (32). Fluorescent sulfate modified latex microspheres (0.2 μm, 505/515 ex/em, FluoSpheres, Life Technologies) were conjugated to the gel surfaces of polyacrylamide substrates with shear moduli of 6.4 kPa after treatment with 1 mg/ml of dopamine hydrochloride (Sigma-Aldrich) dissolved in 50 mM HEPES solution (pH 8.5). Cells were transfected with scramble or CBX5 or G9a siRNA and then transferred on the gel plates overnight before traction force measurements. Images of gel surface-conjugated fluorescent beads were acquired for each cell before and after trypsinization using a Nikon ECLIPSE Ti microscope at 10X magnification. Traction forces were evaluated by measuring bead displacement fields and computing corresponding traction fields using TractionsForAll (http://www.mayo.edu/research/labs/tissue-repair-mechanobiology/software).

Real-time PCR

Total mRNA was isolated and the relative gene expression was analyzed as described in the online supplement.

Protein extraction and Western Blotting analysis

Western blotting analysis of protein lysates was performed as described in the online supplement.

Wound healing assay

Cell migration was evaluated using wound healing assay, as previously described. After scramble- or CBX5 siRNA transfection of cells in 24 well plates, a single scratch was made with sterile 200 μl pipette tip to obtain a cell-free area, followed by washing of cell monolayer with
serum-free medium and treatment with TGFβ (2ng/ml). Cells were photographed at 12 and 24 hours using Olympus CKX53 inverted microscope equipped with a digital camera. The wound area was measured using ImageJ software.

**FACS sorting**

Single cells were sorted from mice lungs after bleomycin or vehicle delivery as described in the online supplement.

**Mouse model of bleomycin-induced lung injury**

Mouse lung fibrosis was induced with bleomycin (BLEO; Fresenius Kabi) delivered intratracheally (1.1 U/kg) to the lungs using MicroSprayer® Aerosolizer (Penn-Century, Philadelphia, PA, USA) as previously described (32). The Sham mice received sterile 0.9% saline instead using identical methods. Body weight was monitored daily. For the BIX01294 study, mice were weighed every 24 hours, and both groups were then randomized at day 10 into BIX01294 and control treatment groups. On single dose of BIX01294 (5mg/kg) was intraperitoneally delivered at day 10 following bleomycin administration. The control groups of mice received the equivalent vehicle dose of PBS. Ten days following BIX01294 treatment, mice were sacrificed and the right lungs were inflated with 4% paraformaldehyde (PFA) and further incubated in 4% PFA for 24 hours prior processing for paraffin embedding. The left lobe of the lung was snap frozen in liquid nitrogen for RNA isolation and hydroxyproline assay. For experiments with the *col1a2*-creER(T)-g9a<sup>fl/fl</sup> transgenic mice tamoxifen (Sigma-Aldrich) dissolved in corn oil was injected i.p. at 5 doses of 0.1 mg/g body weight to induce Cre-mediated recombination. Experimental procedures were approved by the Mayo Clinic Institutional Animal Care and Use Committee and the animals were handled in accordance with their guidelines.
**ECM deposition assay**

Cellular ECM deposition was measured using primary Collagen I (Novus NB600-408) and Fibronectin (Sigma sc-9068) antibodies as described in the online supplement.

**Collagen gel contraction assay**

After scramble or CBX5 or G9a siRNA transfection (48 hours), cells were mixed into collagen solution (2mg/ml) in presence of TGFβ (2ng/ml). Collagen/cell suspensions were incubated at 37 °C for 1 h to allow the collagen gels to solidify. Gels were then gently lifted from the wells and the diameter of each gel was measured using an inverted microscope.

**Chromatin Immunoprecipitation (ChIP)**

ChIP assay was performed following the manufacturer’s instructions (ChIP Assay Kit, Millipore). Cells were subjected to cross-linking with 1% formaldehyde in medium for 10 min at 37 °C and then lysed in SDS buffer for 10 min on ice. Chromatin was sonicated to shear DNA to an average length of 0.2–1.0 kb. Antibodies against CBX5 (Cell Signaling, 2616S) and H3K9me2 (Cell Signaling, 4658P) were used for immunoprecipitation. Normal mouse IgG (Santa Cruz) was used as negative control. The immunoprecipitation was heated to reverse the formaldehyde cross-linking and the DNA fragments in the precipitates were purified by phenol/chloroform extraction and ethanol precipitation. The immunoprecipitated DNA was quantified by real-time PCR. Primers were designed to amplify the proximal promoter region of *PPARGC1A* gene. Primers are listed in Supplement Table 1.
Statistics
Data are presented as the mean ± standard error of the mean (SEM). Comparison between two groups was calculated with Student’s paired t test and group analysis was compared by using one-way ANOVA with Tukey’s multiple comparison’s test using GraphPad Prism 6.0 (La Jolla, CA) with statistical significance defined as p< 0.05. Results are expressed throughout with box and whisker plots showing min to max, quartile, and median.

Author contributions
G.L. and D.J.T. conceived and designed the project. G.L., N.C, J.A.M., D.J., Q.T., KMC, A.J.H, A.A. performed the experiments. G.L., Y.S.P., R.A.U., G.L., D.J.T interpreted the data. G.L and D.J.T wrote the manuscript. A.C.R. reviewed mouse tissue slides. All authors edited and approved the manuscript.

Acknowledgement
Funding support provided by NIH HL142596 (GL) and HL092961 (DJT), HL13320 (DJT)

Study approval
All animal experiments were carried out under protocols approved by the Mayo Clinic Institutional Animal Care and Use Committee (IACUC), and the animals were handled in accordance to their guidelines.
References


FIGURE 1

A  

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ACTA2 Fold Change</th>
<th>COL1A1 Fold Change</th>
<th>FN1 Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>TGFβ</td>
<td>4</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>CBX5 siRNA</td>
<td>8</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

B  

- -  + CBX5 siRNA  + TGFβ  
42  =  αSMA  37  =  GAPDH  25  =  CBX5

C  

Immuno-ECM assay

Control  TGFβ

Collagen I  Fibronectin

C. siRNA  C. siRNA  CBX5 siRNA

Fibronectin  Collagen I

D  

-  +  -  +  -  +  -  +

T0  T12h  T24h

Control  CBX5 siRNA

Cell migration (# cells/field)

12h  24h

CBX5 siRNA

E  

IPF-derived FBs

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ACTA2 Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1</td>
</tr>
<tr>
<td>TGFβ</td>
<td>4</td>
</tr>
<tr>
<td>CBX5 siRNA</td>
<td>8</td>
</tr>
</tbody>
</table>

F  

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ACTA2 Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1</td>
</tr>
<tr>
<td>TGFβ</td>
<td>2</td>
</tr>
<tr>
<td>CBX5 siRNA</td>
<td>1</td>
</tr>
</tbody>
</table>

G  

Transcriptionally inactive chromatin state

CBX5  CBX5  CBX5  Pot II

Anti-fibrotic genes
**Figure 1. CBX5 silencing inhibits TGFβ-induced lung fibroblast activation.**

A. IMR90 lung fibroblasts were transfected with CBX5 siRNA for 48 hours followed by TGFβ stimulation for 24 hours. qPCR showed that TGFβ-stimulated pro-fibrotic gene expression was significantly impaired in CBX5-silenced fibroblasts compared to those transfected with control siRNA (n=3). Data are shown as mean ± SEM of three independent experiments performed in duplicate. (*p<0.05, **p<0.01, ***p<0.001, by 1-way ANOVA with Turkey’s multiple comparisons test).

B. Western Blotting showing that CBX5 knockdown in lung fibroblasts blocked TGFβ-stimulated αSMA expression (representative blot of n=3).

C. CBX5-silenced lung fibroblasts displayed deficient ECM protein deposition in response to TGFβ as demonstrated by the immuno-ECM assay (IECM). Both Fibronectin and Collagen I were significantly reduced in CBX5-silenced fibroblasts compared to control cells. Data shown are representative of three independent experiments. Results are expressed as mean ± SEM (**p<0.01 by 2-tailed, paired t-test). Scale bar: 10µm.

D. Scratch assay shows reduced migratory capacity of CBX5-silenced lung fibroblasts in response to TGFβ compared to control cells. Diminished cell migration was significant at 12 hours, and remained impaired at 24 hours following TGFβ exposure. Data represent the mean ± SEM from one representative experiment performed in triplicate (**p<0.01 by 2-tailed, paired t-test). Scale bar: 10µm.

E. qPCR analysis showing that siRNA knockdown of CBX5 in IPF-derived fibroblasts inhibits TGFβ-induced ACTA2 gene expression (n=3). Data are shown as mean ± SEM of three different IPF cell lines (*p<0.05, ***p<0.001, by 1-way ANOVA with Turkey’s multiple comparisons test).

F. ACTA2 gene expression is also significantly reduced in CBX5-silenced IPF fibroblasts in absence of TGFβ (n=4). Data are shown as mean ± SEM of four different IPF cell lines (***p<0.001 by 2-tailed, paired t-test).

G. Schematic representation showing interaction of CBX5 with methylated (me) histone 3 on proximal gene promoters.
FIGURE 2

A Tissue stiffness

Soft (1kPa)

Stiff (50kPa)

B

Mouse lung FBs

H3K9me2/3 DAPI αSMA

DAPI αSMA

D

0 0 1 3 5 10 BIX01294 (μM)

- + + + + + TGFβ

αSMA

GAPDH

H3K9me2/3 H3

0.2 64 0.2 64 kPa

C

- + + + + + TGFβ

TGFβ CBX5 siRNA G9a siRNA

αSMA

GAPDH

H3K9me2 H3K9me3

0.2 64 kPa

D

0 0 1 3 5 10 BIX01294 (μM)

- + + + + + TGFβ

αSMA

GAPDH

37

17

Plastic

E

0 1 2 4 6 Time (h)

- + + + + + BIX01294 (3μM)

GAPDH

H3K9me2 H3K9me3

G

Control-siRNA CBX5-siRNA G9a-siRNA

TGFβ

Gel area (%)

F

Traction Force

RMS Traction (Pa)

- + + + + + TGFβ

- - - - - - CBX5 siRNA G9a siRNA

G

Control-siRNA CBX5-siRNA G9a-siRNA

TGFβ

Gel area (%)

H

ACTA2

COL1A1

I

ACTA2

COL1A1

ACTA2

COL1A1

ACTA2

COL1A1

ACTA2

COL1A1

ACTA2

COL1A1

ACTA2

COL1A1

ACTA2

COL1A1
Figure 2. Matrix stiffness and TGFβ stimulate global H3K9 methylation to promote lung fibroblast activation. A. Representative IF images showing increased αSMA expression and increased global H3K9me2/3 in freshly isolated mouse lung fibroblasts cultured on stiff hydrogels (50kPa) compared to soft hydrogel (1kPA) Scale bars: 20µm. B. Western blotting analysis showing increased H3K9me2/3 in fibroblasts seeded on stiff substrates (64kPa) compared to those seeded on soft substrates. H3K9 methylation was further increased by TGFβ (representative blot of n=3). C. Western blotting analysis shows that the G9a inhibitor BIX01294 inhibits matrix stiffness-promoted αSMA expression and H3K9me2 in human lung fibroblasts (representative blot of n=2). D. BIX01294 dose dependently blocks αSMA expression in human lung fibroblasts following TGFβ stimulation (representative blot of n=3). E. Western Blotting analysis shows that inhibition of G9a time dependently reduces global H3K9me2 in human lung fibroblasts (representative blot of n=3). F. CBX5 and G9a knockdown in human lung fibroblasts inhibit cell contractility as measured by traction force microscopy (n≥5). (*p<0.05, **p<0.01 by 2-tailed, paired t-test). Representative traction maps are shown. Scale bar: 10µm. G. Fibroblasts treated with CBX5 and G9a siRNA shows reduced gel contraction compared to cells transfected with a control siRNA. Data shown are representative of two independent experiments performed in triplicate (n=3). Results are expressed as mean ± SEM (***p<0.001 by 2-tailed, paired t-test). H. Gene expression analysis by qPCR shows that BIX01294 blocks ACTA2 and COL1A1 gene expression in IPF-derived fibroblasts in response to TGFβ (n=3). Data are shown as mean ± SEM of three different IPF cell lines (*p<0.05, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test). I. Gene expression analysis by qPCR shows that knockdown of G9a in IPF-derived fibroblasts blocks TGFβ-stimulated COL1A1 gene expression and shows a trend toward reduced ACTA2 gene expression (n=3). Data are shown as mean ± SEM of three different IPF cell lines (**p<0.01, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test).
**Figure 3. Nuclear G9a and H3K9 methylation are elevated in fibrotic lung tissues.**

A. Lungs from Col1α1-GFP mice show GFP-labeled fibroblasts expansion following bleomycin challenge (day 10) compared to control lungs. Scale bar: 100µm.  
B. Immunofluorescence images show increased G9a expression in GFP positive fibroblasts from bleomycin-treated lungs compared to fibroblasts from healthy lungs. Fluorescence intensity was measured in GFP positive fibroblasts in normal and bleomycin-treated lung tissues using ImageJ software (n≥10). Data are expressed as mean ± SEM of three normal and four bleomycin-treated lungs (*p<0.05 by 2-tailed, paired t-test). Scale bar: 50µm.  
C. Immunofluorescence images showing elevated H3K9me2 in GFP+ fibroblasts from bleomycin-treated lungs compared to GFP+ fibroblasts from healthy lungs (n≥10). Data are expressed as mean ± SEM of four normal and four bleomycin-treated lungs (*p<0.05 by 2-tailed, paired t-test). Scale bar: 50µm.  
D. Immunofluorescence images showing increased H3K9me2 in lung tissues from IPF patients compared to healthy lungs (n≥10). Data are expressed as mean ± SEM of three normal and three IPF lungs (**p<0.01 by 2-tailed, paired t-test). Scale bar: 50µM.  
E. Western blotting showing CBX5 and G9a expression in IPF-derived and normal lung fibroblasts. Densitometry analysis demonstrated significant upregulation of CBX5 in IPF-derived fibroblasts compared to normal fibroblasts. No significant difference was observed in G9a expression (n=5). Data are expressed as mean ± SEM of 5 normal and 5 IPF-derived fibroblasts (*p<0.05 by 2-tailed, paired t-test).
FIGURE 4

A. Mouse lungs

- Digesting enzymes
- CD45 Ab
- CD31 Ab
- CD326 Ab

B. Non-cultured GFP+ FBs

- Fn1
- Ppargc1a

C. Cultured GFP+ FBs

- Sham
- Bleomycin

D. Mouse lung FBs

- Collagen I

E. Bleomycin BIX01294

- 48 hours Post-injection

F. Time(hr)

- 0 6 24 48

- BIX01294

- GAPDH

- H3K9me2/3

G. Ppargc1a

- 12 12 Days(Bleo)

- BIX01294

- Ppara

- 12 12 Days(Bleo)

- BIX01294
Figure 4. Fibroblasts isolated form fibrotic lungs display sustained peroxisomal gene repression in vitro. A. Lungs from bleomycin- or vehicle-treated Col1α1-GFP mice were harvested two weeks following bleomycin administration. FACS sorting was employed to isolate GFP+ fibroblasts from diseased and healthy lungs. Antibodies against markers for epithelial (CD326), endothelial cells (CD31), and leukocytes (CD45), were included in the analysis. Gating strategy includes CD45+ cell exclusion, doublets and dead cells exclusion (not shown). FACS analysis reveals increased number of GFP+ fibroblasts and higher GFP intensity in fibroblasts from diseased lungs compared to healthy lungs. B. qPCR on FACS-sorted lung fibroblasts shows elevation of Fn1 gene expression and repression of peroxisomal genes, including Ppara and Ppargc1a, but not Pparg, in diseased compared to normal fibroblasts (n≥5). Results are expressed as mean ± SEM (**p<0.05, ***p<0.001 by 2-tailed, paired t-test). C. Representative images showing cultured GFP+ fibroblasts from bleomycin-treated or healthy lungs. Scale bar: 10μm. Western blotting showing elevated αSMA expression and sustained PGC1α and PPARα repression in cultured GFP+ lung fibroblasts from diseased lungs compared to healthy GFP+ fibroblasts (Sham n=2, Bleo n=2). D. IECM analysis shows that diseased mouse lung fibroblasts display increased collagen I deposition compared to normal ones. Inhibition of G9a by BIX01294 in diseased fibroblasts significantly reduces collagen I deposition to a level comparable to normal fibroblasts. Results are expressed as mean ± SEM (**p<0.01, ***p<0.01 by 1-way ANOVA with Turkey’s multiple comparisons test). E. Experimental strategy to evaluate peroxisomal gene expression in diseased lung fibroblasts in vivo following G9a inhibition by BIX01294. F. Western blotting image showing reduced H3K92/3me in whole lung at 24 and 48 hours following BIX01294 administration (representative blot of n=2). G. qPCR shows Ppargc1a and Ppara elevation in fibroblasts from BIX01294-treated compared to control mice (n=6). Results are expressed as mean ± SEM (*p<0.05, ***p<0.001 by 2-tailed, paired t-test).
FIGURE 5

A

HL-FBs

- + TGFβ

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

PPARGC1A

Fold change

- + TGFβ

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

IPF-FBs

- + TGFβ

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

PPARGC1A

Fold change

- + TGFβ

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E

Soft

Fibrosis-suppressor genes

Pro-fibrotic genes

Stiff

PPARGC1A

Fold change

- + CBX5 siRNA

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

F

- + CBX5 siRNA

<table>
<thead>
<tr>
<th>100</th>
<th>PGC1α</th>
<th>PPARα</th>
<th>PPARγ</th>
<th>GAPDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>55</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Figure 5. Inhibition of CBX5 in activated lung fibroblasts promotes upregulation of peroxisomal genes in vitro.**

A. Western blotting analysis shows that TGFβ potently inhibits peroxisomal protein expression in normal human lung fibroblasts (representative blot of n=3). Cells were incubated with TGFβ for 24 hours. B. qPCR analysis reveals that inhibition of CBX5 in normal human lung fibroblasts prevents TGFβ-inhibited peroxisomal gene expression (n=3). Data are shown as mean ± SEM of three independent experiments performed in duplicate. (*p<0.05, **p<0.01, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test). C. Western blotting analysis shows strong repression of peroxisomal proteins by TGFβ in IPF-derived fibroblasts (representative blot of n=3). D. Similarly to normal lung fibroblasts, inhibition of CBX5 in IPF-derived fibroblasts blocks TGFβ-inhibited peroxisomal gene expression (n=3). Data are shown as mean ± SEM of three independent experiments performed in duplicate (*p<0.05, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test). E. Gene expression analysis shows PPARA and PPARGC1A gene repression in normal lung fibroblasts seeded on stiff substrates (64kPa) compared to soft (0.2kPa) (n=3). Data are shown as mean ± SEM of three independent experiments performed in duplicate (*p<0.05 by 2-tailed, paired t-test). F. Western blotting analysis shows downregulation of PPARα and PGC1α in lung fibroblasts cultured on stiff compared to soft substrates. CBX5 silencing blocks matrix stiffness-mediated PPARα and PGC1α downregulation in lung fibroblasts representative blot of (n=2).
Figure 6. PGC1α Inhibition by G9a/CBX5 pathway is an early and necessary step in TGFβ-mediated fibroblast activation. A. Western Blotting showing reduction of H3K9me2/3 in IPF-derived fibroblasts exposed to BIX01294 for 2, 4 and 6 hours (representative blot of n=2) B. qPCR of IPF-derived fibroblasts treated with TGFβ shows increase of ACTA2 and COL1A1 gene expression at 12 hours following TGFβ exposure. BIX01294 treatment reduces ACTA2 and COL1A1 elevation by TGFβ at 12 hours, but has no effect at 4 or 8 hours. Data are shown as mean ± SEM of four different IPF cell lines (*p<0.05 by 2-tailed, paired t-test). C. qPCR analysis showing that TGFβ inhibits PPARA, PPARG and PPARGC1A gene expression starting at 4 hours following treatment. BIX01294 treatment prevents PPARGC1A gene repression by TGFβ, without significant effect on PPARA and PPARG. Data are shown as mean ± SEM of four different IPF cell lines (**p<0.01 by 2-tailed, paired t-test). D. BIX01294 significantly reduces ACTA2 gene expression and elevated PPARGC1A gene transcripts. Data are shown as mean ± SEM of four different IPF cell lines (**p<0.01, ***p<0.001 by 2-tailed, paired t-test). E,F. PPARγ or PPARα inhibition by siRNA or antagonists in BIX01294-treated of CBX5-silenced fibroblasts fails to block the beneficial effects of inhibiting G9a or CBX5 in TGFβ-treated fibroblasts. G. Inhibition of PGC1α by siRNA in BIX01294-treated or CBX5-silenced fibroblasts restores the elevation of ACTA2 by TGFβ. Data are shown as mean ± SEM of three independent experiments performed in duplicate (*p<0.05, **p<0.01, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test). H. qPCR analysis showing that inhibition of PGC1α in CBX5-silenced fibroblasts promotes COL1A1 gene elevation in response to TGFβ. Data are shown as mean ± SEM of four independent experiments performed in duplicate (*p<0.05 by 1-way ANOVA with Turkey’s multiple comparisons test).
**FIGURE 7**

**A**

PPARGC1A proximal promoter

<table>
<thead>
<tr>
<th>-159</th>
<th>TSS(+1)</th>
<th>+85</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>**</td>
<td>*</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>-377</th>
<th>-282</th>
<th>TSS(+1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>**</td>
<td>*</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>-935</th>
<th>-827</th>
<th>TSS(+1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

**B**

<table>
<thead>
<tr>
<th>-159</th>
<th>TSS(+1)</th>
<th>+85</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>*</td>
<td>**</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>-377</th>
<th>-282</th>
<th>TSS(+1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>*</td>
<td>**</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>-935</th>
<th>-827</th>
<th>TSS(+1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>*</td>
<td>**</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**C**

PPARGC1A

<table>
<thead>
<tr>
<th>TGFβ</th>
<th>CBX5 siRNA</th>
<th>CREB siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>% Input</td>
<td>**</td>
<td>p=0.09</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**D**

ACTA2

<table>
<thead>
<tr>
<th>TGFβ</th>
<th>CBX5 siRNA</th>
<th>CREB siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTA2 Fold change</td>
<td>***</td>
<td>**</td>
</tr>
<tr>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

**E**

Transcriptionally inactive chromatin

Transcriptionally active chromatin
Figure 7. TGFβ enhances CBX5 recruitment and H3K9me mark enrichment at the *PPARGC1A* gene promoter. **A.** Chromatin Immunoprecipitation (ChIP) analysis showing CBX5 enrichment at the proximal promoter of *PPARGC1A* gene in human lung fibroblasts cultured on stiff plastic substrates. TGFβ further elevates CBX5 recruitment at *PPARGC1A* gene promoter (n=3). Data are shown as mean ± SEM (*p<0.05 by 2-tailed, paired t-test). **B.** ChIP analysis shows increased H3K9me2 mark decoration at the *PPARGC1A* gene promoter in human lung fibroblasts in response to TGFβ. BIX01294 treatment significantly reduces H3K9 di-methylation at the *PPARGC1A* gene promoter in response to TGFβ. Three adjacent promoter regions were selected based on their affinity for transcription factors; starting from the TSS are CREB1, MEF2 and FoxO1 respectively (n=3). Data are shown as mean ± SEM (*p<0.05 by 2-tailed, paired t-test) **C.** qPCR analysis showing that inhibition of the transcription factor CREB by siRNA in CBX5-silenced fibroblasts reduces *PPARGC1A* gene expression. Data are shown as mean ± SEM of three independent experiments performed in duplicate (*p<0.05 by 1-way ANOVA with Turkey’s multiple comparisons test). **D.** CREB1 knockdown in lung fibroblasts reduces the beneficial effects of inhibiting CBX5 in TGFβ-treated fibroblasts. Data are shown as mean ± SEM of four independent experiments performed in duplicate (*p<0.05, ***p<0.001 by 1-way ANOVA with Turkey’s multiple comparisons test). **E.** Schematic representation of the proposed mechanism by which CBX5 binding to *PPARGC1A* gene promoter masks CREB1 binding site and inhibits *PPARGC1A* gene transcription.
**FIGURE 8**

**A**  
BIX01294 (IP)  
Bleomycin challenge  
Day 0  
BIX01294 (5mg/kg)  
Day 10  
Lung harvesting  
Day 20

**B**  
Ppargc1a  

**C**  
Fn1  

**D**  
Ctgf  

**E**  
Sham  
Bleo 10d  
Bleo 20d  
Bleo 20d + BIX

**F**  
Ashcroft Score  

**G**  
Hydroxyproline ($\mu$g/mg)  

**H**  
Col1a2-CreER(T):g9a$^{fl/fl}$  
Tamoxifen  
Harvest

**I**  
DAPI  
PDGFRα  
G9a  
MERGE

**J**  
Col1a2-CreER(T):g9a$^{fl/fl}$  
Col1a2-CreER(T)xg9a$^{fl/fl}$  
sham  
Bleo  
g9a$^{fl/fl}$ (Control)  
Bleo + Tam  

**K**  
H3K9me2  

**L**  
Ashcroft Score  

**M**  
Hydroxyproline (µg/mg protein)
Figure 8. Inhibition of G9a following bleomycin challenge promotes \( Ppargc1a \) gene expression and attenuates lung fibrosis. A. Schematic showing experimental workflow. B. qPCR showing \( Ppargc1a \) gene repression following bleomycin delivery. One single dose of BIX01294 partially restores \( Ppargc1a \) gene expression compared to vehicle-treated animals (n≥5). Data are shown as mean ± SEM (*\( p < 0.05 \), ***\( p < 0.001 \) by 1-way ANOVA with Turkey’s multiple comparisons test). D. qPCR shows reduced \( Fn1 \) and \( Ctgf \) transcripts in BIX01294-treated mice lungs compared to vehicle-treated animals (n≥6). Data are shown as mean ± SEM (*\( p < 0.05 \), ***\( p < 0.001 \) by 1-way ANOVA with Turkey’s multiple comparisons test). E. Representative pictures of Masson’s trichome-stained lung tissues. Scale bar: 200µm. F. H&E stained lung sections were scored using Ashcroft method. G. Hydroxyproline assay was used to evaluate collagen deposition in the lungs. Sham control (n=8), Bleo 20 days control (n=12) and Bleo 20 days BIX01294 (n=11). Data are shown as mean ± SEM (**\( p < 0.01 \) by 1-way ANOVA with Turkey’s multiple comparisons test). H. Strategy for inducible knockout of G9a in COL1α2 expressing cells. \( Col1a2\)-CreER:g9a\(^{flt}\) mice were treated with bleomycin, followed by 5 doses of tamoxifen (0.1mg/g) starting at day 3. I. Immunofluorescence images show G9a deletion in PDGFRα+ cells. Scale bar: 10µm. J. Representative pictures of Masson’s trichome-stained lung tissues. Scale bar: 200µm. K. Reduced H3K9me2 in fibroblasts from tamoxifen-treated \( Col1a2\)-CreER(T):g9a\(^{flt}\) compared to g9a\(^{flt}\) control mice. L. H&E stained lung sections were scored using Ashcroft method. M. Bleomycin significantly increases hydroxyproline content in the lungs of control mice \( (Col1a2\)-CreER(T):g9a\(^{flt}\) mice not treated with tamoxifen (n=7), as well as g9a\(^{flt}\) and \( Col1a2\)-CreER(T) control groups treated with tamoxifen (n=7)), but not in mice with conditional deletion of G9a in fibroblasts \( (Col1a2\)-CreER(T):g9a\(^{flt}\) group treated with tamoxifen, n=7) compared to uninjured controls (n=5). Data are shown as means ± SEM, **\( p < 0.01 \), ***\( p < 0.001 \) by 1-way ANOVA with Turkey’s multiple comparisons test.
Figure 9. Schematic representation of the mechanism leading to CBX5/G9a/H3K9me-mediated *PPARGC1A* gene repression and lung fibroblast activation in response to TGFβ and matrix stiffness.